Financial Strains Persist for Lyra Despite Focus on Clinical Milestones Lyra Therapeutics ended 2024 with a net loss of $93.4 million, even as R&D expenses fell. The company’s cash reserves declined to $40.6 million, expected to last into Q1 2026. Management is pinning hopes on the ENLIGHTEN 2 Phase 3 trial results, anticipated in Q2 2025, to guide future strategy.34